metalloproteinase inhibitor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to metalloproteinase inhibitor: metalloprotease inhibitor

metalloproteinase inhibitor

Any of numerous compounds that inhibit the activity of the metalloproteinase family of enzymes. These agents share the ability to suppress or eliminate the enzyme activity of the metalloproteinases. Agents identified in this group include the tetracycline antibiotics, numerous specially designed synthetic peptides and proteins, chemicals such as ethylenediaminetetra-acetic acid (EDTA), and a variety of agents used in cancer chemotherapy. Synonym: metalloprotease inhibitor
See also: inhibitor
References in periodicals archive ?
BB-3644 is a second-generation matrix metalloproteinase inhibitor.
Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer; BB-3644, a follow-on to marimastat, is in Phase I development for cancer; BB-10153 has completed Phase I development for cardiovascular disease; BB-2827, a collagenase inhibitor for inflammation, is in Phase I development; and E21R, a modified GM-CSF, has completed Phase I development.
As MMP-9 and MMP-2 can degrade Type IV, Type VII collagen and laminin, doxycycline and steroids, both metalloproteinase inhibitors, are commonly used in the treatment of RCES.
New bio-medicinal applications such as anticancer and AIDS therapy as well as matrix metalloproteinase inhibitors have also been investigated [6].
Overall, Linder recommended using a formula that contains broad-spectrum UV protection, matrix metalloproteinase inhibitors (MMPi), antioxidants, retinoids, ascorbic acid and peptides to improve collagen and matrix protection and production.
Effects of matrix metalloproteinase inhibitors on bone resorption and orthodontic tooth movement.
Promising new treatment options include novel delivery systems (inhalation or intracavitary chemotherapy) use of immunomodulators such as liposome-encapsulated muramyl tripeptide-phosphatidyle thanolamine, antimetastatic agents such as inhibitors of angiogenesis (interferons, thalidomide), matrix metalloproteinase inhibitors and minocycline dietary modifications and genetherapy (Clifford et al.
Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases [Electronic version].
They cover carbonic anhydrase inhibitors and activators, matrix metalloproteinase inhibitors, bacterial zinc protease inhibitors, and other enzymes containing zinc.
Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study.

Full browser ?